DAL BEN, Diego
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.204
EU - Europa 6.284
AS - Asia 3.617
SA - Sud America 514
AF - Africa 69
Continente sconosciuto - Info sul continente non disponibili 28
OC - Oceania 7
Totale 21.723
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.880
PL - Polonia 1.708
CN - Cina 1.623
RU - Federazione Russa 1.323
IT - Italia 1.051
SG - Singapore 1.003
DE - Germania 556
BR - Brasile 440
GB - Regno Unito 360
UA - Ucraina 334
HK - Hong Kong 326
CA - Canada 285
SE - Svezia 255
FR - Francia 233
FI - Finlandia 168
KR - Corea 151
VN - Vietnam 144
TR - Turchia 127
IE - Irlanda 87
IN - India 64
JP - Giappone 44
BE - Belgio 39
NL - Olanda 34
AR - Argentina 32
EU - Europa 27
ZA - Sudafrica 27
BD - Bangladesh 26
MX - Messico 25
ES - Italia 22
AT - Austria 21
CZ - Repubblica Ceca 15
EC - Ecuador 13
AE - Emirati Arabi Uniti 12
LT - Lituania 11
RO - Romania 11
IR - Iran 10
KE - Kenya 9
TW - Taiwan 9
CH - Svizzera 8
CO - Colombia 8
ID - Indonesia 8
RS - Serbia 8
TN - Tunisia 8
DK - Danimarca 7
PE - Perù 7
PK - Pakistan 7
PY - Paraguay 7
UZ - Uzbekistan 7
IQ - Iraq 6
JO - Giordania 6
LB - Libano 6
SA - Arabia Saudita 6
AM - Armenia 5
AU - Australia 5
EG - Egitto 5
IL - Israele 5
MA - Marocco 5
VE - Venezuela 5
AL - Albania 4
AZ - Azerbaigian 4
BG - Bulgaria 4
DZ - Algeria 4
HR - Croazia 4
GR - Grecia 3
HU - Ungheria 3
LV - Lettonia 3
NO - Norvegia 3
PH - Filippine 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GE - Georgia 2
KH - Cambogia 2
NI - Nicaragua 2
NP - Nepal 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
CL - Cile 1
CM - Camerun 1
DM - Dominica 1
EE - Estonia 1
GD - Grenada 1
HN - Honduras 1
JM - Giamaica 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
ME - Montenegro 1
MQ - Martinica 1
MU - Mauritius 1
MW - Malawi 1
MY - Malesia 1
NG - Nigeria 1
OM - Oman 1
PA - Panama 1
Totale 21.713
Salva come PNG Salva come JPEG
Città #
Warsaw 1.484
Fairfield 1.295
Woodbridge 971
Ashburn 924
Jacksonville 793
Houston 619
Chandler 567
Seattle 537
Wilmington 514
Ann Arbor 483
Cambridge 449
Singapore 426
Boardman 351
Dallas 350
Hong Kong 312
Beijing 268
Camerino 257
Nanjing 244
Kraków 213
Toronto 199
Los Angeles 168
The Dalles 134
Seoul 127
San Mateo 117
Tongling 116
Dearborn 111
Lawrence 111
Princeton 111
New York 109
Columbus 107
Istanbul 103
London 102
Moscow 91
Ogden 89
Dublin 85
Düsseldorf 81
San Diego 73
Nanchang 71
Buffalo 69
Shanghai 67
Chicago 65
Helsinki 65
Milan 60
Lachine 57
São Paulo 55
Guangzhou 54
Council Bluffs 51
Munich 51
Dong Ket 49
Tianjin 48
Kunming 46
Ho Chi Minh City 43
Shenyang 43
Brussels 39
Jiaxing 38
Hebei 36
Centro 34
Rome 32
Tokyo 31
Santa Clara 30
Frankfurt am Main 25
Hangzhou 25
Philadelphia 24
San Francisco 24
Atlanta 23
Changsha 23
Jinan 23
Wuhan 23
Falls Church 22
Redwood City 22
Hefei 20
Ningbo 20
Norwalk 20
Phoenix 20
Poplar 20
Redondo Beach 20
Scafati 20
Denver 19
Chennai 17
Hanoi 16
Jinhua 16
Johannesburg 16
Nuremberg 16
Orem 16
Turku 16
Verona 16
Zhengzhou 16
Bologna 15
Manchester 15
Stockholm 15
Venezia 15
Brooklyn 14
Montreal 14
Rio de Janeiro 14
Salt Lake City 14
Tampa 13
Ancona 12
Boston 12
Nürnberg 12
Taizhou 12
Totale 14.940
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 616
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 403
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 382
Overview on Radiolabel-Free in Vitro Assays for GPCRs 378
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 353
Pharmacological characterization of the GPR17 receptor dual profile 351
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 338
Stabilization of the cyclodecadiene derivative isofuranodiene by silver (I) coordination. Mechanistic and biological aspects 338
The G Protein-Coupled Receptor GPR17: Overview and Update 323
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 323
Emerging Roles of Purinergic Signaling in Diabetes 320
GPR17 receptor modulators and their therapeutic implications: review of recent patents 276
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 274
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 270
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 269
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 265
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 261
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 251
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 250
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 248
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 243
P2X7 Receptor as a Therapeutic Target 242
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 231
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 227
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 224
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 221
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 214
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 212
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 211
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 210
New sensible method to quantize the intestinal absorption of receptor ligands 208
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 207
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 206
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 205
Identification of a specific residue that confers BzATP sensitivity to P2X2 receptors 202
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 201
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 200
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 200
Antiviral properties of deazaadenine nucleoside derivatives 199
Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel (18)F-labelled PET tracer targeting P2X7 199
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 198
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 198
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 195
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 195
Interaction model for anthracycline activity against DNA topoisomerase II 194
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 192
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 192
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 191
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 188
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 187
Adenosine receptor modeling: what does the A2A crystal structure tell us? 187
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes 187
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 186
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 185
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 184
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 183
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 180
Amide bond direction modulates G-quadruplex recognition and telomerase inhibition by 2,6 and 2,7 bis-substituted anthracenedione derivatives 178
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 175
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 175
The P2X7 Receptor in Infection and Inflammation 175
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 175
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 174
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists 173
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 171
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 168
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 167
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 166
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 163
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 162
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 161
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 160
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 154
DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation 154
I protocolli operativi nella violenza di genere 153
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 152
Development of novel pyridazinone-based adenosine receptor ligands 150
Rational design of new competitive inhibitors of human CK2 activity 146
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 144
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 141
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 140
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 139
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 138
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 137
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 136
Substituted adenine derivatives as novel P2X3 receptor ligands 135
null 134
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 132
7th Joint Italian-German Purine Club Meeting - “Advances in basic and translational purinergic research” - 20-22 luglio 2017 129
Existence of snoRNA, microRNA, piRNA characteristics in a novel non-coding RNA: x-ncRNA and its biological implication in Homo sapiens 128
New purine derivatives as P2X3 receptor antagonists 128
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A(3) receptor 128
GTP-Eu binding assay optimization for the adenosine A3 receptor ligands screening 124
Letters in Drug Design & Discovery 123
Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: Molecular docking analysis and pharmacological studies 118
A2A adenosine receptor ligands: effects on alcohol intake in alcohol-preferring rats 118
New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A2A adenosine receptor antagonists 118
“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 116
Toward the rational design of Protein Kinase CK2 inhibitors 114
Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential 112
Totale 20.257
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.730
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.730
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.362 0 0 0 0 0 450 666 100 299 222 369 256
2021/20221.488 184 371 33 41 67 66 86 124 111 145 92 168
2022/20231.440 164 103 56 230 137 188 9 74 245 70 109 55
2023/20241.247 161 64 80 49 57 114 65 92 138 44 45 338
2024/20254.107 180 74 330 195 135 258 476 1.025 340 283 277 534
2025/20262.962 367 349 702 813 641 90 0 0 0 0 0 0
Totale 22.135